Rapid response to avapritinib of acute myeloid leukemia with t(8;21) and KIT mutation relapse post allo-HSCT.

Bone marrow aspiration suggested relapse of AML, and the patient achieved I AML1/ETO i negative status after four cycles of chemotherapy (details unknown). Donor lymphocyte infusion (DLI) is the main immunotherapy given for relapse post-HSCT, and although ~60% of relapsed AML patients achieve complete remission after chemotherapy plus DLI, only ~33% achieve long-term leukemia-free survival [[8]]. Acute myeloid leukemia (AML) encompasses a clinically and genetically diverse set of blood cancers caused by abnormally rapid expansion of myeloid progenitor cells in the bone marrow and extramedullary sites leading to disrupted hematopoiesis [[1]]. To our knowledge, this is the first report of avapritinib use for treating relapsed AML post allo-HSCT, and the outcome in this patient supports further investigation of avapritinib therapy for AML. [Extracted from the article]